RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has demonstrated CV benefits. This study found sotagliflozin reduced the risk…
RT @CJASN: Sotagliflozin is a dual SGLT1 and 2 inhibitor that has demonstrated CV benefits. This study found sotagliflozin reduced the risk…
@nkf @DrDeidraCrews @eric_weinhandl @AmakaEMD @SusanQuaggin @sylviaerosas @goKDIGO @ASNKidney @NatRevNeph Sotagliflozin reduced kidney and cardiorenal risks in type 2 diabetes with CKD. https://t.co/hOzHM4kjkD
Give that drug an indication for slowing CKD progression. Sotagliflozin and Kidney Outcomes, Kidney Function, and... : Clinical Journal of the American Society of Nephrology https://t.co/fzHuBxAXRT
RT @CJASN: In the initial analysis of SCORED, reconciliation of eGFR laboratory data & case report forms was not completed. This analysis,…
RT @CJASN: In the initial analysis of SCORED, reconciliation of eGFR laboratory data & case report forms was not completed. This analysis,…
RT @CJASN: In the initial analysis of SCORED, reconciliation of eGFR laboratory data & case report forms was not completed. This analysis,…
In the initial analysis of SCORED, reconciliation of eGFR laboratory data & case report forms was not completed. This analysis, using the complete laboratory dataset, found sotagliflozin reduced risk of kidney & cardiorenal composite endpoints http
Remember how disappointed SOLOIST-WHF was interrupted due to loss of funding? However, sotagliflozin shows 🫘 better kidney outcome 🫀cardiorenal composite outcome: in 4.5% in sotagliflozin gr and 5.8% in placebo gr (HR 0.77, 95% CI 0.65-0.91) @CJASN htt
【事前指定追加解析: SCORED】CKDを伴う2型糖尿病患者へのソタグリフロジンの投与は、プラセボの投与と比較して、腎臓複合転帰(eGFRの50%以上の持続した低下、eGFR<15mL/min/1.73m^2、透析または腎移植)のリスク減少と関連した。 #ペ読 https://t.co/IjHJFFNGs4
RT @Miguel_A_Maria: Sotagliflozin and Kidney Outcomes, Kidney Function, and Albuminuria in T2DM and CKD: A Secondary Analysis of the SCORED…
RT @Miguel_A_Maria: Sotagliflozin and Kidney Outcomes, Kidney Function, and Albuminuria in T2DM and CKD: A Secondary Analysis of the SCORED…
RT @Miguel_A_Maria: Sotagliflozin and Kidney Outcomes, Kidney Function, and Albuminuria in T2DM and CKD: A Secondary Analysis of the SCORED…
Sotagliflozin and Kidney Outcomes, Kidney Function, and Albuminuria in T2DM and CKD: A Secondary Analysis of the SCORED Trial https://t.co/ABTlT3xvWG Interesante @ralcazara @SENefrologia @redGDPS https://t.co/OeFT9ukQR8
RT @eric_weinhandl: SCORED is not the trial to prove renoprotection, but the hazard ratios are perfectly compelling. Sotagliflozin FTW. So…
RT @eric_weinhandl: SCORED is not the trial to prove renoprotection, but the hazard ratios are perfectly compelling. Sotagliflozin FTW. So…
SCORED is not the trial to prove renoprotection, but the hazard ratios are perfectly compelling. Sotagliflozin FTW. Sotagliflozin and Kidney Outcomes, Kidney Function, and... : Clinical Journal of the American Society of Nephrology https://t.co/tiT4UMa8lG
RT @gunnar_heine: SCORED scores: A more comprehensive look at SCORED data bases suggests clear nephroprotective effects of the SGLT-1 + 2 i…
RT @gunnar_heine: SCORED scores: A more comprehensive look at SCORED data bases suggests clear nephroprotective effects of the SGLT-1 + 2 i…
RT @gunnar_heine: SCORED scores: A more comprehensive look at SCORED data bases suggests clear nephroprotective effects of the SGLT-1 + 2 i…
SCORED scores: A more comprehensive look at SCORED data bases suggests clear nephroprotective effects of the SGLT-1 + 2 inhibibor sotagliflozin From @DLBHATTMD and collegues. https://t.co/d1GShqiu90 @MarcusSaemann @floriancustodis @HaraldSou @kidney_bo